Novo Nordisk A/S (NYSE:NVO) Shares Sold by Trust Co. of Vermont

Trust Co. of Vermont lowered its position in shares of Novo Nordisk A/S (NYSE:NVO) by 3.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,981 shares of the company’s stock after selling 1,044 shares during the period. Trust Co. of Vermont’s holdings in Novo Nordisk A/S were worth $2,321,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in NVO. Natixis Advisors LLC grew its stake in Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after purchasing an additional 80,070 shares in the last quarter. Norman Fields Gottscho Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after acquiring an additional 19,870 shares during the last quarter. Talbot Financial LLC acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at approximately $4,066,000. Versant Capital Management Inc acquired a new position in Novo Nordisk A/S in the fourth quarter worth $86,000. Finally, Zions Bancorporation N.A. increased its stake in Novo Nordisk A/S by 57.0% during the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after purchasing an additional 6,726 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on NVO. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Stock Performance

Shares of NVO traded down $4.33 during trading hours on Friday, reaching $78.74. 21,239,835 shares of the company traded hands, compared to its average volume of 8,206,201. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15. The stock has a market cap of $353.33 billion, a P/E ratio of 25.48, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45. The stock’s fifty day moving average is $98.33 and its 200 day moving average is $117.69. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.